Glucosidase I releases the distal 1,2-glucosyl residue in the Glc 3 Man 9 GlcNAc 2 precursor immediately after its transfer from the dolichol-P-P-linked intermediate in the endoplasmic reticulum and triggers the processes for the post-translational remodeling, folding and maturation of N-linked glycoproteins. The enzyme has been purified and characterized from several eukaryotic systems. Its cDNA and the gene have also been cloned. The enzyme is a target for the development of drugs for several pathological conditions. A structural analysis on the biochemically-purified enzyme has been hampered because of its low abundance and unstable character. The recombinant enzyme has not been obtained in quantity and characterized.
4 mutants that accumulate Glc 3 Man 8-9 GlcNAc 2 -containing glycans (Boisson et al., 2001; Gillmor et al., 2002) . These mutants are severely impaired during embryo morphogenesis and exhibit dramatic alterations in their cellular differentiation during development.
Inhibition of glucosidase I has been shown to interfere with the normal folding, transport and egress of glycoproteins from the ER, and can lead to aggregation and degradation of the improperly folded glycoproteins (Sears and Wong, 1998) . Further, it has been shown to affect the infectivity of viruses, e.g., HIV and Hepatitis types B and C Fleet et al., 1998; Zitzmann et al., 1999) . The use of glucosidase I inhibitor, 1-deoxynojirimycin (DNM) and its N-butyl and N-nonyl derivatives was shown to affect the assembly of viral glycolproteins in HIV-infected cells, impairing the infectivity and release of virus from the cells . DNM binds to the substrate-binding region of the active site of glucosidases I and II and acts as a competitive inhibitor during catalysis by these enzymes (Hettkamp et al., 1984) . Its Nalkyl derivatives are more selective for inhibiting glucosidase I than glucosidase II (Tan et al. , 1991) .
Photoaffinity labeling is a powerful and sensitive approach for gaining an insight into ligandprotein interactions and has been often employed in identifying the ligand and substrate binding domains of receptors and enzymes, respectively (Gartner, 2003; Zhang et al., 2003) . A critical requirement for the interaction is that the probe must be highly specific for its target site in the macromolecule. In the context of glycobiology, such probes of sugar-nucleotides have served as important tools for identifying and characterizing a number of glycosyltransferases (for example, Shailubhai et al., 1990; Wang-Gillam et al., 2000) . Glucosidase I from several sources has been purified to homogeneity and characterized (Shailubhai et al., 1987; Bause et al., 1989) ; however, the three dimensional structure of the enzyme has not been elucidated and the nature of its active site remains to be defined. An understanding of the structure-function relationship of the enzyme would provide a scaffold for designing therapeutics to treat diseases involving glycoprotein interactions. As a first step towards gaining an insight into the active site of glucosidase I, we report the synthesis of a novel photoactive probe, -azidosalicylamido-butyl-5-amido-pentyl-1-deoxynojirimycin (ASBA-P-DNM), from DNM; it was rendered radioactive by iodination with 125 I for use in labeling the active site of the enzyme. The compound showed high affinity for the native enzyme and its photolysis provided a facile means to label the enzyme.
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The data in Table I represent IC 50 values, i.e., the concentrations of DNM and its derivatives required to inhibit 50% of the enzyme activity under the conditions of assay, calculated from the results in Fig. 2 . Substitution of alkyl groups on DNM that have a polar group in close proximity to the ring nitrogen dramatically lowered the inhibitory action of DNM on the catalytic activity of glucosidase I. The IC 50 values for AE-DNM, CM-DNM and AP-DNM were 146, >500 and >500 µM, respectively, compared to 2.75 µM for DNM.
An alkylation of DNM, as in N-methyl-DNM, AA-P-DNM and ASBA-P-DNM enhances the potency of DNM (IC 50 0.33, 0.30 and 0.42 µM, respectively). The introduction of a charged group, even on a relatively small alkyl chain as in CP-DNM lowers the inhibitory potential of the compound for the enzyme (compare IC 50 7.16 µM for CP-DNM versus 2.75 µM for DNM).
The compound AA-P-DNM contains a six carbon, hydrophobic arm separating the DNM moiety from the azidoanilinyl photoactive center and has a favorable IC 50 (0.30 µM) for tagging glucosidase I after photolysis. However, we were unsuccessful in obtaining the radioiodinated form of this compound in good yield under mild iodination conditions; apparently the azido group sufficiently deactivates the phenyl ring and its presence does not favor further substitution.
Under strong oxidizing conditions the DNM moiety became unstable and yielded several products with much reduced level of inhibitory potency towards glucosidase I. Therefore, AA-P-DNM was not found to be suitable for use in radiolabeling the enzyme at the substrate-binding site.
Synthesis and characterization of [ 125 I]ASBA-P-DNM
pentyl-1-deoxynojirimycin ([ 125 I]ASBA-P-DNM) was prepared by coupling 4-( -azidosalicylamido)-butylamine (ASBA) to CP-DNM through amidation [Materials and Methods] . In contrast to AA-P-DNM, the ASBA-P-DNM could be readily iodinated with 125 I because of the activating influence of the -OH group on the phenyl ring. The UV absorption spectrum of a 25 µM aqueous solution of ASBA-P-DNM is shown in Fig. 3 . Without irradiation, ASBA-P-DNM had a maximum absorption at 270 nm with a shoulder at 315 nm, characteristic of an aryl azide. UV irradiation of this compound for different time intervals with 254 nm UV light gradually decreased its absorption at 270 nm (Fig. 3, inset) , where the peak disappeared after 20 seconds of exposure to UV, indicating the photolysis of the aryl azide.
The results of It was earlier shown that DNM-protection of the active site of glucosidase I prevented its inactivation by phenylglyoxal, a reagent that chemically modifies the arginine residues in 9 proteins. This and other observations led us to propose the ERHLDLRCW motif at the active site of the enzyme (Romaniouk and Vijay,1997 ). An experiment was conducted to modify the arginine residues in the enzyme with phenylglyoxal ( et al. , 1988; Sels et al. , 1999) , malignancy (Ranes et al. , 2001 ),
Gaucher's disease (Priestman et al. , 2000) , Hepatitis B and C (Zitzmann et al., 1999) and AIDS (Fleet et al. , 1988) . The architecture of the active si te of a number ofglucosidases, particularly the glycoprotein processing glucosidase I, has not been defined. Due to its critical juxtaposition in the pathway of protein N-glycosylation, it is important to have this information for a more rational design of specific therapeutics. A large-scale purification of the enzyme from animal or plant tissues, that would be amenable for crystallization to conduct structural analysis, is difficult given its low abundance and unstable character. The cDNA and the gene of the enzyme have been cloned, but structural studies or analysis of the active site of the recombinant enzyme have not been reported. Upon transient overexpression in COS1 cells, the cDNA of the human hippocampus enzyme showed only a 4-fold increase in the enzyme activity over the background, endogenous enzyme activity (Kalz-Fuller et al. , 1995) . In our studies with the expression of the mouse cDNA in Sf9 cells, the recombinant enzyme requires the cotransfection of cDNAs of the chaperones calnexin, calreticulin and ERp57 to obtain significant catalytic activity (unpublished). Apparently, the recombinant enzyme does not fold well after expression. Until a structural model for the enzyme can be developed after crystallization or through modeling and computational analysis, an investigator must try strategies of solution biochemistry to minimally gain some insight into the active site of the enzyme. Photoaffinity labeling at or near the substrate-binding region of the purified enzyme offers a useful approach for such an effort. Importantly, the probe must be specific for the native enzyme and be highly reactive to reach out within a reasonable distance from the binding region within the active site.
Several laboratories have shown that N-alkylation of DNM increases its inhibitory potential for glucosidase I (Tan et al. , 1991; Mellor et al. , 2002) . Consistent with the previous studies, we observed that CP-DNM, which has a five carbon spacer between its carboxyl group and the nitrogen in the ring component, was more effective than several other alkyl derivatives of DNM and could serve well for the attachment of a photoactive group. Its extension with 4-azidoaniline (AA) or -azido-salicyl-butyl-amine (ASBA) enhanced the IC 50 of DNM for the enzyme. This
indicates that the N-substitution of DNM that gives rise to AA-P-DNM and ASBA-P-DNM allows alignment and interaction of these derivatives with the hydrophobic region surrounding the catalytic pocket of the enzyme. However, only ASBA-P-DNM was found to be suitable for radiolabeling with 125 I because of the mild conditions under which it could be rendered radioactive without destroying its integrity.
The photo-labeling of glucosidase I with [ 125 I]ASBA-P-DNM was directed towards the active site because labeling decreased significantly in the presence of N-methyl DNM (Fig. 5B ) and was not observed after modifying the enzyme with phenylglyoxal (Fig. 5C ). There was also a remarkable reduction in the photo-labeling of the 24 kDa peptide fragment obtained after digestion of the enzyme with V8 protease that had been labeled with [ 125 I]ASBA-P-DNM in the presence of DNM (Fig. 6A, lane 3) . When thermally denatured enzyme was labeled with the probe, again there was very little labeling of any specific region of the enzyme. These observations support the view that the active site of the enzyme resides within the 24 kDa 12 peptide and the probe can gain entry into it under the conditions employed in this study. The positive Western blot of the V8-digested, 24 kDa peptide with mono-specific antipeptide [582] [583] [584] [585] [586] [587] [588] [589] [590] [591] [592] [593] [594] [595] [596] [597] [598] antibody (Fig. 6C) further support this observation. Earlier, we had observed that glucosidase is a multi-domain protein in which the active site resided within a 39 kDa segment (Shailubhai et al. , 1991) .
In conclusion, our data show that (Volker et al., 2002) indicating that these amino acids are essential for glucosidase I activity.
This observation is consistent with our earlier proposal that the motif E 594 RHLDLRCW 602
represented the substrate binding motif in the enzyme in the rat mammary gland. This proposal was developed by identifying cysteine, arginine and tryptophan at the active site by modifying the amino acid residues of the enzyme after loading DNM into the active site of the enzyme (Pukhazhenthi et al. , 1994, Romaniouk and Vijay, 1997 ). An analysis of the enzyme, as given above, provides a direct means of verifying this proposal. Our current experiments are designed to test this hypothesis.
Materials and Methods

Materials
All reagents and chemicals used in this study were purchased from commercially available sources and were of the highest purity. 1-Deoxynojirimycin (DNM) was a kind gift from Drs. D. N-5-carboxypentyl-1-deoxynojirimycin (CP-DNM) was synthesized according to the published procedure (Hettkamp et al., 1984 washed successively with a dilute solution of H 2 SO 4 , water, 5% NaHCO 3 and water. The filtrate was dried and crystallized in ethanol. Activated t-Boc-alanyl-o-pentafluorophenol (1.2 mmol, 0.43 g) was then reacted with DNM (0.8 mmol, 0.16 g) in 2 ml of DMSO at room temperature for 24 hours and the reaction products were analyzed by TLC using ethyl acetate: acetic acid (15:1) as the solvent. The reaction mixture was loaded on a silica gel column; the column was washed with hexane, and t-Boc-alanyl-DNM was eluted with a hexane: ethyl acetate (1:4) solution. AP-DNM was obtained by removal of the t-Boc group from t-Boc-alanyl-DNM (0.3 mmol) by treatment with trifluoroacetic acid (2 ml) in 2 ml of methanol at room temperature for 1 hour. Reaction mixture was dried and t-Boc was removed by extraction with diethyl ether.
Purity of AP-DNM product was determined through TLC analysis, using the solvent system 1- N-(2-aminoethanoyl)-1-deoxynojirimycin (AE-DNM) was prepared from t-Boc-glycine and DNM according to the protocol used to prepare AP-DNM. The purity of the AE-DNM compound was analyzed by TLC using solvent system 1-butanol: acetic acid: water (4:1:1 4-Azidoanilido-N-pentyl -1-deoxynojirimycin (AA-P-DNM) was synthesized by conjugating 4-azidoaniline to CP-DNM by the amidation procedure previously described (Sehgal and Vijay, 1994 analyzing the UV absorption spectrum of the compound before and after exposure to 254 nm UV light. Absorption spectrum of AA-P-DNM was recorded on a Perkin Elmer UV/VIS Lambda 2 spectrophotometer, where the maximum absorption peak of the compound was found to be at 265 nm. Attempts to radioiodinate the phenyl ring of AA-P-DNM using the chloroamine T method (Greenwood et al., 1963) under mild conditions were unsuccessful; iodination at temperatures above RT affected the functional groups on the DNM moiety.
Synthesis of photoactive compound [ 125 I]4-(p-azidosalicylamido)butyl-5-amido-pentyl-1-deoxynojirimycin ([ 125 I]ASBA-P-DNM)
4-(p-Azidosalicylamido)butyl-5-amido-pentyl -1-deoxynojirimycin (ASBA-P-DNM) was prepared in stoichiometric yield by the amidation procedure given above (Sehgal and Vijay, 1994) . All steps described below were performed under subdued, indirect light. N-5-carboxypentyl-1-DNM (0.054 mmol) was reacted with 4-(p-azidosalicylamido)-butylamine (ASBA, 0.092 mmol), EDC (23.4 mmol), and NHS (3 mmol) in 1 ml of 60% DMF, 25 mM MES buffer (pH 6.5) solution, and the reaction incubated for 24 hours at room temperature. The reaction solution was concentrated and the ASBA-P-DNM product was purified by preparative TLC using solvent system chloroform: methanol: water (10:10:1). Phenyl]). UV-visible spectra of ASBA-P-DNM samples (25 µM) in water were analyzed before and after exposure to 254 nm UV light at 5, 10, and 20-second time intervals. ASBA-P-DNM samples were exposed to UV light at a 7 cm distance.
[ 125 I]ASBA-P-DNM was prepared by radioiodinating ASBA-P-DNM using IODO-GEN tubes.
125 I was first activated by incubating 1 mCi of Na 125 I in 20 µl of 25 mM phosphate buffer (pH 7.2) in an IODO-GEN tube for 6 min while shaking every 30 seconds. Activated iodine solution was transferred to 2 µl of ASBA-P-DNM (25 mM) solution in water and was left for 10 min at room temperature. [ 125 I]ASBA-P-DNM was purified by preparative silica gel TLC on aluminum-backed plates that were developed in chloroform: methanol: water (10:10:1). Position of the radioiodinated compound was located by autoradiography of the TLC plate and the product was purified by elution from silica gel with methanol: water (1:1) solution.
[ 125 I]ASBA-was purified from this extract as previously described (Shailubhai et al. , 1987 
Expression of glucosidase II and measurement of its activity
Glucosidase II-, as fusion protein Glc--MycHis 6 , and glucosidase II-subunit were cloned and expressed in a Baculovirus system (Feng, J., Romaniouk, A., Samal, S. and Vijay, I ., manuscript in preparation). The co-expressed forms of the subunits of the enzyme were purified on Ni -NTA-agarose column. The fusion protein was catalytically active. Its enzyme activity was determined as given above for glucosidase I except that 7,000 cpm of the radioactive oligosaccharide [Glc-3 H] Glc 2 Man 9 GlcNAc 2 was used as the substrate. It showed a specific activity of 2170 units per mg [one unit of enzyme activity is defined as the amount of enzyme protein required to hydrolyze 10% of the corresponding substrate in 30 min at 37°C].
Modification of glucosidase I with phenylglyoxal
A 10 µg of glucosidase I enzyme sample was incubated with 100 mM phosphate buffer (pH 7.5) and 20 mM phenylglyoxal for one hour at room temparature (Romaniouk and Vijay, 1997) .
The modified enzyme was dialyzed and used for photo-labeling with [ 125 I]ASBA-P-DNM.
Photo-labeling of glucosidase I
A 10 µg of purified glucosidase I in 2.3 ml of 25 mM phosphate buffer (pH 6.8) The crude microsomal extract was photo-labeled with 0.5 µM [ 125 I]ASBA-P-DNM using the same procedure as for glucosidase I, but without the use of any competitors.
V8 digestion
A 20 µg portion of glucosidase I dissolved in 100 µL of 4 M urea was diluted with 100 µL of 20 V-8 Protease was added to enzyme buffer mixture, and glucosidase I was digested at 37° C for 24 hours.
Monospecific antibody to peptide fragment of glucosidase I
Through the genome database search, we identified a conservative peptide fragment of human glucosidase I, 582 DDYPRASHPSVTERHLD 598 , that is immunogenic and specific for the glucosidase I enzyme. The immunogenic peptide 582 DDYPRASHPSVTERHLD 598 and the monospecific antibody to the peptide sequence were prepared by Research Genetics, Huntsville, Alabama. Anti-rabbit IgG was used as secondary antibody for western analysis. were also photolabeled with the radioactive photoprobe for 10%SDS-PAGE and stained with Coomassie Blue (1) and subjected to autoradiography (2). Table I . Inhibitory constants of DNM and its derivatives for bovine glucosidase I. The IC 50 values were calculated from the data in Fig. 2 .
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